Related Experiment Video
Updated: Oct 10, 2026

Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness
Published on: May 2, 2017
The growth hormone/insulin-like growth factor axis in critical illness
1Department of Medicine and GCRC, SUNY Health Science Center Stony Brook, New York 11794-8154, USA. mgelato@notes.cc.sunysb.edu
Abstract:
Over the past several years, we have studied a variety of clinical conditions that are characterized by significant alterations in the GH/IGF system that might contribute to catabolism. Our studies have focused in detail on IGF-I and -II and the major IGFBPs in the circulation, IGFBP-3, -1, and -2; GH was also measured in some of these studies. In light of a recent study that has raised concerns about the use of GH in critically ill patients, we now review the changes in the GH/IGF axis during critical illness, the interaction between cytokines and the GH/IGF axis, and the safety and efficacy of GH therapy in critical illness. We conclude that it is premature to recommend interruption of GH therapy in patients with documented GH deficiency during periods of acute illness.
Related Concept Videos
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Hypoglycemia and Glucagon
Insulin: The Receptor and Signaling Pathways
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
Hypothalamic-Pituitary Axis
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...